TristelTSNLF +6.35%97 Return-on-Tangible-Equity is 33.37% as of Dec. 2025, which is 13% above its 10-year median of 29.58. GuruFocus rates TSNLF with a GF Score™ of 97/100 and a GF Value™ of $6.07 (Fairly Valued). The stock has 1 warning sign investors should review. Among 759 Medical Devices & Instruments companies, Tristel ranks better than 89.86% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Tristel's annualized net income for the quarter that ended in Dec. 2025 was $10.59 Mil. Tristel's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $31.73 Mil. Therefore, Tristel's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 33.37%.
The historical rank and industry rank for Tristel's Return-on-Tangible-Equity or its related term are showing as below:
TSNLF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.97 Med: 29.58 Max: 39.51
Current: 34.34
During the past 13 years, Tristel's highest Return-on-Tangible-Equity was 39.51%. The lowest was 4.97%. And the median was 29.58%.
TSNLF's Return-on-Tangible-Equity is ranked better than 89.86% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.07
vs TSNLF: 34.34
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Tristel Return-on-Tangible-Equity Related Terms
Tristel Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Tristel's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSNLF vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Tristel's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tristel Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tristel's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Tristel's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 33.37% mean?
Tristel (TSNLF) has a Return-on-Tangible-Equity of 33.37% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Tristel and its competitors. This is 13% above median its historical median of 29.58. Over the past decade, Tristel's Return-on-Tangible-Equity has ranged from 4.97 to 39.51. According to the industry distribution chart, Tristel ranks #77 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 10.1%.
Is Tristel's Return-on-Tangible-Equity too high?
Tristel's current Return-on-Tangible-Equity of 33.37% is 13% above median its 10-year median of 29.58. Over the past 10 years, this metric has ranged from a low of 4.97 to a high of 39.51. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.07. Tristel's value of 33.37% is 719.9% above this industry median. Based on the distribution chart, Tristel ranks #77 out of 759 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Tristel has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tristel's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tristel ranks #77 out of 759 companies for Return-on-Tangible-Equity. This places Tristel in the top 10% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.07. Tristel's value of 33.37% is 719.9% above this benchmark. Historically, Tristel's own Return-on-Tangible-Equity has ranged from 4.97 to 39.51 over the past decade. While the company's 10-year median is 29.58 vs. the industry median of 4.07, Tristel has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.07, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tristel's current Return-on-Tangible-Equity of 33.37% is 719.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Tristel and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tristel's current Return-on-Tangible-Equity is 33.37%, which is 13% above median its own 10-year median of 29.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tristel stock overvalued right now?
Based on GuruFocus' analysis, Tristel (TSNLF) is currently considered Fairly Valued. The stock's GF Value™ is $6.07, compared to a current price of $5.53 — trading 8.9% below its estimated fair value. The current Return-on-Tangible-Equity is 33.37%, which is 13% above median its 10-year median of 29.58 and 719.9% above the Medical Devices & Instruments industry median of 4.07. Tristel's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Tristel (TSNLF), the current Return-on-Tangible-Equity is 33.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tristel (TSNLF) Overvalued in 2026?
Based on GuruFocus' analysis, Tristel stock appears to be undervalued.
The current stock price of $5.53 is trading 8.9% below its estimated GF Value™ of $6.07.
GuruFocus considers Tristel to be Fairly Valued.
Key valuation signals for TSNLF:
Return-on-Tangible-Equity: 33.37% (13% above median its 10-year median of 29.58)
GF Value™: $6.07 vs. price of $5.53 (8.9% below fair value)
Industry Position: 719.9% above the Medical Devices & Instruments median (#77 of 759)
No single metric tells the full story. See the TSNLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tristel PLC's business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand and for the sporicidal disinfection of environmental surfaces under the Cache brand. Its operating segments include hospital medical device decontamination products used predominantly for infection control in hospitals; the manufacture and sale of hospital environmental surface disinfection products; and pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare. The company generates the majority of its revenue from hospital medical device decontamination and operates geographically in the UK and overseas markets.
97GF Score
Get the complete analysis for TSNLF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNLF has been successfully added to your 
